Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-NeoB + Ribociclib + Fulvestrant in ER+/HER2-/GRPR+ Advanced Breast Cancer
NCT05870579Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of AAA503 in breast cancer, sponsored by Novartis. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events and Serious Adverse Events up to 60 months and 1 more. Started Nov 2023; status: active, not recruiting.
02
Drugs
AAA503
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05870579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870579.